Targeted Advances in ALK+ NSCLC

In a wide-ranging discussion, Alexander Drilon, MD; Julia Rotow, MD; Thomas E. Stinchcombe, MD; and Ashish Saxena, MD, PhD, provide expert insight on developments in ALK-positive non–small cell lung cancer.

Advanced, recurrent, and metastatic NSCLC is often associated with poor prognosis, and treatment is aimed to extend survival and provide symptom management.

Ashish Saxena, MD, PhD, discusses the future of next-generation ALK inhibitors in non–small cell lung cancer.

Ashish Saxena, MD, PhD, discusses available next-generation ALK inhibitors in non–small cell lung cancer.

Julia Rotow, MD, discusses remaining questions with brigatinib in ALK-positive non­–small cell lung cancer.

Julia Rotow, MD, discusses the implications of next-generation ALK inhibitors in non–small cell lung cancer.

Julia Rotow, MD, discusses the utility of brigatinib versus crizotinib for the first-line treatment of patients with ALK-positive non

Alexander Drilon, MD, discusses the utility of brigatinib in ALK-positive non–small cell lung cancer.

Thomas E. Stinchcombe, MD, discusses the results of the randomized phase III ALTA-1L trial in ALK-positive non–small cell lung cancer.

Ashish Saxena, MD, PhD, discusses the importance of initial therapy selection in ALK-positive non–small cell lung cancer.

Alexander Drilon, MD, discusses the potential utility of immunotherapy in ALK fusion-positive non–small cell lung cancer.

Thomas E. Stinchcombe, MD, discusses the importance of molecular testing in ALK-positive non–small cell lung cancer.

Julia Rotow, MD, discusses updated data from the phase III ALEX trial in ALK-positive non–small cell lung cancer.

Alexander Drilon, MD, discusses the safety profile of brigatinib in ALK-positive non­–small cell lung cancer.

Ashish Saxena, MD, PhD, discusses the importance of biomarker testing for stage IV ALK-positive non–small cell lung cancer.

Julia Rotow, MD, discusses the safety profile of brigatinib in ALK-positive non–small cell lung cancer.

Thomas E. Stinchcombe, MD, discusses remaining challenges in ALK-positive non­–small cell lung cancer.